Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient

A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

from Top Health News -- ScienceDaily https://ift.tt/3xJJDMS